How to enter the Russian pharmaceutical market
The emergence of big domestic drug companies is reshaping Russia’s pharmaceutical patent landscape. Mikhail Khmara and Yana Lipatova of ARS-Patent explain how originator and generic companies can navigate the country’s changing IP rules
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
